Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Core Insights - Shattuck Labs, Inc. has submitted an Investigational New Drug (IND) application for SL-325, with clearance expected in Q3 2025, and plans to begin dosing the first participant in a Phase 1 clinical trial in the same quarter [1][6][10] - The company reported a cash balance of approximately $50.5 million at the end of Q2 2025, with additional funding from a recent oversubscribed private placement expected to support operations into 2029 [1][9] - SL-325 is a first-in-class DR3 blocking antibody aimed at treating inflammatory bowel disease (IBD) and other immune-mediated diseases, with multiple preclinical bispecific antibodies also in development [6][10][11] Recent Developments - The second quarter of 2025 was marked by the successful submission of the IND application to the FDA, with expectations to start enrollment in the Phase 1 trial later this quarter and complete it by Q2 2026 [2][6] - The Phase 1 trial will assess safety, tolerability, immunogenicity, and pharmacokinetics in healthy volunteers, with the first participant expected to be dosed in Q3 2025 [6][10] - Shattuck is also developing multiple preclinical DR3-based bispecific antibodies targeting IBD and plans to nominate a lead candidate from this pipeline in 2025 [6][10] Financial Performance - As of June 30, 2025, cash and cash equivalents were approximately $50.5 million, down from $105.3 million a year earlier [13] - Research and Development (R&D) expenses for Q2 2025 were $8.7 million, a decrease from $19.2 million in Q2 2024 [13] - The net loss for Q2 2025 was $12.5 million, or $0.24 per share, compared to a net loss of $21.6 million, or $0.42 per share, in the same quarter of the previous year [13][19]